Tick-borne encephalitis (TBE) vaccine to medically immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study.

MLA

Hertzell, Katarina Brodin, et al. “Tick-Borne Encephalitis (TBE) Vaccine to Medically Immunosuppressed Patients with Rheumatoid Arthritis: A Prospective, Open-Label, Multi-Centre Study.” Vaccine, vol. 34, no. 5, Jan. 2016, pp. 650–55. EBSCOhost, https://doi.org/10.1016/j.vaccine.2015.12.029.

APA

Hertzell, K. B., Pauksens, K., Rombo, L., Knight, A., Vene, S., & Askling, H. H. (2016). Tick-borne encephalitis (TBE) vaccine to medically immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study. Vaccine, 34(5), 650–655. https://doi.org/10.1016/j.vaccine.2015.12.029

Chicago

Hertzell, Katarina Brodin, Karlis Pauksens, Lars Rombo, Ann Knight, Sirkka Vene, and Helena H Askling. 2016. “Tick-Borne Encephalitis (TBE) Vaccine to Medically Immunosuppressed Patients with Rheumatoid Arthritis: A Prospective, Open-Label, Multi-Centre Study.” Vaccine 34 (5): 650–55. doi:10.1016/j.vaccine.2015.12.029.